Innoviva Price to Sales Ratio 2010-2024 | INVA
Historical PS ratio values for Innoviva (INVA) over the last 10 years. The current P/S ratio for Innoviva as of May 10, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Innoviva P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-05-10 |
15.60 |
|
3.98 |
| 2024-03-31 |
15.24 |
$3.92 |
3.89 |
| 2023-12-31 |
16.04 |
$3.86 |
4.16 |
| 2023-09-30 |
12.99 |
$3.56 |
3.65 |
| 2023-06-30 |
12.73 |
$3.48 |
3.66 |
| 2023-03-31 |
11.25 |
$3.37 |
3.33 |
| 2022-12-31 |
13.25 |
$3.48 |
3.80 |
| 2022-09-30 |
11.61 |
$3.94 |
2.95 |
| 2022-06-30 |
14.76 |
$4.43 |
3.33 |
| 2022-03-31 |
19.35 |
$4.30 |
4.50 |
| 2021-12-31 |
17.25 |
$4.09 |
4.21 |
| 2021-09-30 |
16.71 |
$3.75 |
4.46 |
| 2021-06-30 |
13.41 |
$3.33 |
4.02 |
| 2021-03-31 |
11.95 |
$3.03 |
3.95 |
| 2020-12-31 |
12.39 |
$2.97 |
4.18 |
| 2020-09-30 |
10.45 |
$2.84 |
3.68 |
| 2020-06-30 |
13.98 |
$2.64 |
5.30 |
| 2020-03-31 |
11.76 |
$2.51 |
4.69 |
| 2019-12-31 |
14.16 |
$2.30 |
6.15 |
| 2019-09-30 |
10.54 |
$2.34 |
4.51 |
| 2019-06-30 |
14.56 |
$2.30 |
6.33 |
| 2019-03-31 |
14.03 |
$2.33 |
6.03 |
| 2018-12-31 |
17.45 |
$2.30 |
7.58 |
| 2018-09-30 |
15.24 |
$2.18 |
7.00 |
| 2018-06-30 |
13.80 |
$2.04 |
6.77 |
| 2018-03-31 |
16.67 |
$1.93 |
8.62 |
| 2017-12-31 |
14.19 |
$1.81 |
7.85 |
| 2017-09-30 |
14.12 |
$1.58 |
8.92 |
| 2017-06-30 |
12.80 |
$1.45 |
8.83 |
| 2017-03-31 |
13.83 |
$1.18 |
11.75 |
| 2016-12-31 |
10.70 |
$1.10 |
9.71 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$0.986B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
